Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

The Top 5 Biosimilar Articles for the Week of December 11

December 15th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 11, 2023.

SABCS Posters Evaluate Real-World Outcomes Associated With Ogivri

December 14th 2023

By Skylar Jeremias

Article

Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.

New Interactive Biosimilar Tool Can Help Educate Providers and Patients

December 13th 2023

By Skylar Jeremias

Article

Biosim.care is a new interactive education tool that can help patients, caregivers, and providers navigate decision-making and treatment conversations for multiple disease states.

Eye on Pharma: Hadlima Interchangeability; CHMP Green Lights Ustekinumab; Biosimilars Forum Supports Draft Legislation

December 12th 2023

By Skylar Jeremias

Article

The FDA agreed to review an application for Hadlima (adalimumab biosimilar) to be granted interchangeability; The European Union’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for an ustekinumab biosimilar; the Biosimilars Forum expressed support for a Senate Finance Committee’s draft legislation promoting biosimilars.

Study Shows Similar Efficacy, Drug Survival Rates for Etanercept Biosimilar vs Originator in RA

December 11th 2023

By Cameron Santoro

Article

A national study on patients with rheumatoid arthritis (RA) compares the disease activity and drug survival rate between an etanercept biosimilar and the originator (Enbrel).

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space

December 10th 2023

By Skylar Jeremias

Video

Brian Biehn, senior director of biosimilar commercialization at Cencora, makes predictions for how big regulatory approvals in 2023 will shape the biosimilar space going forward.

Factors Physicians Should Consider When Selecting an Adalimumab Biosimilar

December 9th 2023

By Deana Ferreri, PhD

Article

A review article discussed the characteristics of the available adalimumab biosimilars to help clinicians navigate the various treatment options with their patients.

The Top 5 Biosimilar Articles for the Week of December 4

December 8th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 4, 2023.

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

December 7th 2023

By Laura Joszt

Article

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.

Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab

December 6th 2023

By Skylar Jeremias

Article

Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.